The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate, in patients with prostate cancer including those previously treated with enzalutamide.
 
Jose W. Avitia
No Relationships to Disclose
 
Neal D. Shore
Employment - GenesisCare
Leadership - Alessa Therapeutics; Photocure
Consulting or Advisory Role - Abbvie; AIkido Pharma; Amgen; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Fize Medical; Foundation Medicine; Genesis Cancer Care; Genzyme; Guardant Health; ImmunityBio; Incyte; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myovant Sciences; Myriad Genetics; NGM Biopharmaceuticals; Nonagen Bioscience; Novartis; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; PlatformQ Health; Profound Medical; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion; Vessi Medical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring
Other Relationship - Alessa Therapeutics; Photocure
 
Luke T. Nordquist
No Relationships to Disclose
 
Ryan J. Malone
Consulting or Advisory Role - AdaptiveEndo; AstraZeneca; Janssen Oncology; Specialty Networks
Research Funding - Janssen Oncology
Travel, Accommodations, Expenses - Specialty Networks
 
David Morris
Stock and Other Ownership Interests - UROGPO
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Decipher Biosciences; Janssen Oncology; Merck Serono; Myovant Sciences; Myriad Genetics; Pfizer/EMD Serono; Urogen pharma; UROGPO
Speakers' Bureau - Astellas Medivation; AstraZeneca; Clovis Oncology; Janssen; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca/Merck (Inst); Bayer (Inst); Clovis Oncology (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer/Astellas (Inst); Urogen pharma (Inst)
 
Cody J. Peer
No Relationships to Disclose
 
William Richardson
No Relationships to Disclose
 
Keith Thomas Schmidt
No Relationships to Disclose
 
William Douglas Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); Propella Therapeutics (Inst); TRACON Pharma (Inst)
 
Jacqueline M. Walling
Leadership - Entos AI; Opna; Orbus Therapeutics; Plexxikon; Propella Therapeutics
Stock and Other Ownership Interests - Amgen
Consulting or Advisory Role - Ambagon Therapeutics; Aminex; Black Diamond Therapeutics; Cumulus Oncology; Entos AI; Flag Therapeutics; Harpoon Therapeutics; Janux Therapeutics; Lyell Immunopharma; Myovant Sciences; Nurix; Nuvation Bio; Opna Bio; Orbus Therapeutics; Oryzon Genomics; Plexxikon; Propella Therapeutics; Rgenta; Rhizen Pharmaceuticals; Storm Therapeutics
 
Katherine McDougall
Consulting or Advisory Role - Propella Therapeutics
 
Joel Robert Eisner
Employment - GeneCentric
Stock and Other Ownership Interests - GeneCentric; Innocrin Pharma
Consulting or Advisory Role - Propella Therapeutics
Patents, Royalties, Other Intellectual Property - Provisional patents for GeneCentric and Innocrin Pharma as part of my employments
 
William R. Moore
Employment - Propella Therapeutics; Vizuri
Leadership - Propella Therapeutics; Vizuri
Stock and Other Ownership Interests - Propella Therapeutics; Vizuri
Research Funding - Propella Therapeutics; Vizuri
Patents, Royalties, Other Intellectual Property - I'm an inventor on patents that were assigned to Propella Therapeutics that protect composition of matter, methods of use, and manufacturing of abiraterone decanoate
Travel, Accommodations, Expenses - Propella Therapeutics; Vizuri
 
Ronald F. Tutrone
Employment - Chesapeake Urology
Stock and Other Ownership Interests - Compass Therapeutics; GlaxoSmithKline; Myovant Sciences; Novartis; Nymox; Veru
Consulting or Advisory Role - Exosome Diagnostics; Myovant Sciences; Novartis; Nymox
Speakers' Bureau - Exosome Diagnostics; Medivation/Astellas; Pfizer
Research Funding - Advantagene (Inst); Bayer (Inst); Dendreon (Inst); Exosome Diagnostics (Inst); Genomic Health (Inst); Janssen Oncology (Inst); MDxHealth (Inst); Medivation/Astellas (Inst); Merck (Inst); POINT Biopharma (Inst); Veru (Inst)